SHIJIAZHUANG, China, March 31, 2020 /PRNewswire/ -- On March 31, Shijiazhuang Yiling Pharmaceutical Co., Ltd released a notice that they had received the approval of the modern herbal medicine registration issued by the ministry of health of Thailand. Lianhua Qingwen Capsule is recognized as in line with Thailand's modern herbal medicine standards registration. The registration certificate number is i6300037/63(H).
The functional indications of Lianhua Qingwen Capsule approved by the ministry of health of Thailand are:
Lianhua Qingwen is a patented product of Yiling Pharmaceutical Co., LTD., a category of national essential medicine catalogue and national medical insurance catalogue. It is mainly used for the treatment of cold and flu-related diseases. Lianhua Qingwen products have been listed in the cold and flu-related diseases treatment program by the National Health Commission and the State Administration of Traditional Medicine of China for many times. In 2020, Lianhua Qingwen Capsules/Granules were listed as the recommended drug in the "Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme" (Trial version IV/V/VI/VII) which was jointly issued by the National Health Commission and the State Administration of Traditional Medicine of China.
Lianhua Qingwen Capsule has been approved by the ministry of health of Thailand for the registration of modern herbal medicine, which indicates that the company has the qualification to sell products as a drug in the Thai market and will have a positive impact on its overseas market expansion.
Up to now, in addition to Thailand, Lianhua Qingwen Capsules have been registered in Hong Kong (SAR of China), Macao (SAR of China), Brazil, Indonesia, Canada, Mozambique, and Romania as "Chinese patent medicine", "medicine", "plant medicine", "natural health products", "food supplement" and other identities, and obtained the marketing authorisation.
Read more: http://www.digitaljournal.com/pr/4628222#ixzz6IFN1AkBx
